These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 26852268)

  • 1. Harnessing the Prokaryotic Adaptive Immune System as a Eukaryotic Antiviral Defense.
    Price AA; Grakoui A; Weiss DS
    Trends Microbiol; 2016 Apr; 24(4):294-306. PubMed ID: 26852268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral Goes Viral: Harnessing CRISPR/Cas9 to Combat Viruses in Humans.
    Soppe JA; Lebbink RJ
    Trends Microbiol; 2017 Oct; 25(10):833-850. PubMed ID: 28522157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR-Cas systems: Prokaryotes upgrade to adaptive immunity.
    Barrangou R; Marraffini LA
    Mol Cell; 2014 Apr; 54(2):234-44. PubMed ID: 24766887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptation in CRISPR-Cas Systems.
    Sternberg SH; Richter H; Charpentier E; Qimron U
    Mol Cell; 2016 Mar; 61(6):797-808. PubMed ID: 26949040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. United we stand: big roles for small RNA gene clusters.
    Felden B; Paillard L
    RNA; 2017 Feb; 23(2):131-133. PubMed ID: 27881475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Strategies of Clustered Regularly Interspaced Palindromic Repeats-Cas Systems for Different Viral Infections.
    Wahid B; Usman S; Ali A; Saleem K; Rafique S; Naz Z; Ahsan Ashfaq H; Idrees M
    Viral Immunol; 2017 Oct; 30(8):552-559. PubMed ID: 28825529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clustered regularly interspaced short palindromic repeats: structure, function and application--a review].
    Cui Y; Li Y; Yan Y; Yang R
    Wei Sheng Wu Xue Bao; 2008 Nov; 48(11):1549-55. PubMed ID: 19149174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus.
    Moyo B; Bloom K; Scott T; Ely A; Arbuthnot P
    Virus Res; 2018 Jan; 244():311-320. PubMed ID: 28087399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cas9-mediated targeting of viral RNA in eukaryotic cells.
    Price AA; Sampson TR; Ratner HK; Grakoui A; Weiss DS
    Proc Natl Acad Sci U S A; 2015 May; 112(19):6164-9. PubMed ID: 25918406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prokaryotic homologs of Argonaute proteins are predicted to function as key components of a novel system of defense against mobile genetic elements.
    Makarova KS; Wolf YI; van der Oost J; Koonin EV
    Biol Direct; 2009 Aug; 4():29. PubMed ID: 19706170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The CRISPR case, « ready-made » mutations and Lamarckian evolution of an adaptive immunity system].
    Casane D; Laurenti P
    Med Sci (Paris); 2016; 32(6-7):640-5. PubMed ID: 27406776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of RNA- and DNA-guided antivirus defense systems in prokaryotes and eukaryotes: common ancestry vs convergence.
    Koonin EV
    Biol Direct; 2017 Feb; 12(1):5. PubMed ID: 28187792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programming Native CRISPR Arrays for the Generation of Targeted Immunity.
    Hynes AP; Labrie SJ; Moineau S
    mBio; 2016 May; 7(3):. PubMed ID: 27143383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ecology and evolution of microbial CRISPR-Cas adaptive immune systems.
    Westra ER; van Houte S; Gandon S; Whitaker R
    Philos Trans R Soc Lond B Biol Sci; 2019 May; 374(1772):20190101. PubMed ID: 30905294
    [No Abstract]   [Full Text] [Related]  

  • 15. CRISPR-based technologies: prokaryotic defense weapons repurposed.
    Terns RM; Terns MP
    Trends Genet; 2014 Mar; 30(3):111-8. PubMed ID: 24555991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral diversity threshold for adaptive immunity in prokaryotes.
    Weinberger AD; Wolf YI; Lobkovsky AE; Gilmore MS; Koonin EV
    mBio; 2012 Dec; 3(6):e00456-12. PubMed ID: 23221803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploiting CRISPR/Cas systems for biotechnology.
    Sampson TR; Weiss DS
    Bioessays; 2014 Jan; 36(1):34-8. PubMed ID: 24323919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The application of CRISPR-Cas9 gene editing technology in viral infection diseases].
    Yin LJ; Hu SQ; Guo F
    Yi Chuan; 2015 May; 37(5):412-8. PubMed ID: 25998428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target preference of Type III-A CRISPR-Cas complexes at the transcription bubble.
    Liu TY; Liu JJ; Aditham AJ; Nogales E; Doudna JA
    Nat Commun; 2019 Jul; 10(1):3001. PubMed ID: 31278272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal number of spacers in CRISPR arrays.
    Martynov A; Severinov K; Ispolatov I
    PLoS Comput Biol; 2017 Dec; 13(12):e1005891. PubMed ID: 29253874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.